K. Ozols Cukura diabēts oftalmologa skatījumā

 

Literatūra

  1. Quianzon C.C., Cheikh I. History of insulin. J Community Hosp Intern Med Perspect. 2012 Jul 16;2(2). DOI: 10.3402/jchimp.v2i2.18701. PMID: 23882369; PMCID: PMC3714061.
  2. Owens, David R. et al. l.DF diabetes Atlas: A worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive. Diabetes Research and Clinical Practice, Volume 226, 112346.
  3. The IDF Diabetes Atlas 11th; https://diabetesatlas.org/resources/factsheets/
  4. Li J.Q., Welchowski T., Schmid Met al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020 Jan; 35(1): 11–23. DOI: 10.1007/s10654-019-00560-z. Epub 2019 Sep 12. PMID: 31515657.
  5. Wiemer N.G., Eekhoff E.M., Simsek S., Heine R.J., Ringens P.J., Polak B.C., Dubbelman M. Refractive properties of the healthy human eye during acute hyperglycemia. Graefes Arch Clin Exp Ophthalmol. 2008 Jul; 246(7): 993–998. DOI: 10.1007/s00417-008-0810-y. Epub 2008 Apr 4. PMID: 18389272; PMCID: PMC2413123.
  6. Harding J.J., Egerton M., van Heyningen R., Harding R.S. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br J Ophthalmol. 1993 Jan; 77(1): 2–6. DOI: 10.1136/bjo.77.1.2. PMID: 8435392; PMCID: PMC504412.
  7. Pollreisz A., Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol. 2010; 2010: 608751. DOI: 10.1155/2010/608751. Epub 2010 Jun 17. PMID: 20634936; PMCID: PMC2903955.
  8. Zhao Y.X., Chen X.W. Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies. Int J Ophthalmol. 2017 Sep 18; 10(9): 1430–1435. DOI: 10.18240/ijo.2017.09.16. PMID: 28944204; PMCID: PMC5596230.
  9. Zhao D., Cho J., Kim M.H., Friedman D.S., Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015 Jan; 122(1): 72–78. DOI: 10.1016/j.ophtha.2014.07.051. Epub 2014 Oct 3. PMID: 25283061.
  10. Rubsam A., Parikh S., Fort P.E. Role of inflammation in diabetic retinopathy. Int J Mol Sci 2018; 19: E942.
  11. Campochiaro P.A., Aiello L.P., Rosenfeld P.J. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology 2016; 123: S78–88.
  12. Watanabe D., Suzuma K., Suzuma I., Ohashi H., Ojima T., Kurimoto M., Murakami T., Kimura T., Takagi H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with PDR.
  13. Ogura S., Kurata K., Hattori Y. et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight 2017; 2: e90905.
  14. Sentaro Kusuhara, Yoko Fukushima, Shuntaro Ogura, Pathophysiology of Diabetic Retinopathy: The Old and the New, Diabetes & Metabolism Journal 2018; 42(5): 364–376.
  15. Wong, Tien Y. et al., Guidelines on Diabetic Eye Carel, Ophthalmology, Volume 125, Issue 10, 1608–1622.
  16. American Academy of Pediatrics, Section on Endocrinology and Section on Ophthalmology. Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. Pediatrics. 1998; 101: 313–314.
  17. SentCheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet. 2010 Jul 10; 376(9735): 124–136. DOI: 10.1016/S0140-6736(09)62124-3. Epub 2010 Jun 26. PMID: 20580421.
  18. Cooper B.A. Ten Key Elements of a Diabetes-Related Eye Examination. In: A Practical Guide to Diabetes-Related Eye Care. Arlington (VA): American Diabetes Association; 2022 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582424/ DOI: 10.2337/db20223-4
  19. Shukla U.V., Tripathy K. Diabetic Retinopathy. [Updated 2023 Aug 25]. In: StatPearls [Internet]. Treasure Island(FL): Stat Pearls Publishing; 2025Jan-. Availablefrom: https://www.ncbi.nlm.nih.gov/books/NBK560805/
  20. American Diabetes Association Professional Practice Committee, Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes–2025; Diabetes Care 2025; 48(Suppl. 1): S252–S265.
  21. Royle P., Mistry H., Auguste P., et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jul. (Health Technology Assessment, No. 19.51.) Chapter 2, The landmark trials: Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study.
  22. Kozak I., Luttrull J.K. Modern retinal laser therapy. Saudi Journal of Ophthalmology. 2015; 29(2): 137–146. DOI: 10.1016/j.sjopt.2014.09.001.
  23. Xu Y., Tan C.S. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017 Apr; 37(2): 325–332. DOI: 10.1007/s10792-016-0241-4. Epub 2016 May 28. PMID: 27236451.
  24. Adams B.S., Sorhaitz W., Stringham J. Aflibercept. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582136/
  25. Elman M.J., Bressler N.M., Qin H., et al. Diabetic Retinopathy Clinical Research Network.Expanded year follow-up of ranibizumab plusprompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609–614.
  26. Rittiphairoj T., Mir T.A., Li T., Virgili G. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2020 Nov 17; 11(11): CD005656. DOI: 10.1002/14651858.CD005656.pub3. PMID: 33206392; PMCID: PMC8095060.

Nacionālie partneri

Informatīvie partneri

Starptautiskie partneri